The Technical Analyst
Sigilon Therapeutics, [SGTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Sigilon Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.56% $22.47
America/New_York / 10 aug 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 56.22 mill |
| EPS: | -14.83 |
| P/E: | -1.515 |
| Earnings Date: | Nov 08, 2023 |
| SharesOutstanding: | 2.50 mill |
| Avg Daily Volume: | 0.121 mill |
| RATING 2023-08-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.515 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.26x |
| Company: PE -1.515 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 21.31 - 23.63 ( +/- 5.17%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-08-11 | Flagship Ventures Fund V General Partner Llc | Sell | 113 960 | Common Stock |
| 2023-08-11 | Eli Lilly & Co | Buy | 1 718 493 | Common Stock |
| 2023-08-11 | Cole Douglas G. | Sell | 683 | Stock Option (Right to Buy) |
| 2023-08-11 | Cole Douglas G. | Sell | 683 | Stock Option (Right to Buy) |
| 2023-08-11 | Oesterle Stephen N. | Sell | 683 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 68.73 |
| Last 96 transactions |
| Buy: 15 034 169 | Sell: 5 311 777 |
Forecast:
01:40 - $20.96
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $22.47 (-2.56% ) |
| Volume | 0.0819 mill |
| Avg. Vol. | 0.121 mill |
| % of Avg. Vol | 67.85 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SGTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SGTX
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2023-08-14 07:25:00 - Press Release
Lilly Completes Acquisition Of Sigilon Therapeutics
Indianapolis , aug. 14, 2023 /prnewswire/ -- eli lilly and company (nyse: lly) today announced the successful completion of its acquisition of sigilon therapeutics, inc. (nasdaq: sgtx). the acquisition allows lilly to continue researching and developing encapsulated cell therapies, including sig-002, for the treatment of type 1 diabetes.
2023-07-21 18:17:00 - Press Release
Sigilon Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Sigilon Therapeutics, Inc. - Sgtx
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of sigilon therapeutics, inc. (nasdaqgs: sgtx) to eli lilly and company (nyse: lly). under the terms of the proposed transaction, shareholders of sigilon will receive $14.92 in cash, plus one non-tradeable contingent value right that entitles the holder to receive up to an additional $111.64 per share, for each s.
2023-06-29 06:45:00 - Press Release
Lilly To Acquire Sigilon Therapeutics
Indianapolis and cambridge, mass. , june 29, 2023 /prnewswire/ -- eli lilly and company (nyse: lly) and sigilon therapeutics, inc. (nasdaq: sgtx) today announced a definitive agreement for lilly to acquire sigilon, a biopharmaceutical company that seeks to develop functional cures for patients with a broad range of acute and chronic diseases.
2023-04-18 07:00:00 - Press Release
Sigilon Therapeutics To Present At The Needham Virtual Healthcare Conference
Cambridge, mass., april 18, 2023 (globe newswire) -- sigilon therapeutics, inc. (nasdaq: sgtx), a biotechnology company that seeks to develop functional cures for acute and chronic diseases through its shielded living therapeutics™ platform, today announced that its president and chief executive officer, rogerio vivaldi, m.d., will present a corporate overview during the needham virtual healthcare conference. the presentation will take place on thursday, april 20, 2023 at 10:15 a.m. edt.
2022-04-07 07:00:00 - Press Release
Sigilon Therapeutics To Present At The Needham Healthcare Conference
Cambridge, mass., april 07, 2022 (globe newswire) -- sigilon therapeutics, inc. (nasdaq: sgtx), a biotechnology company that seeks to develop functional cures for chronic diseases through its shielded living therapeutics™ platform, today announced that its president and chief executive officer, rogerio vivaldi, m.d., will present a corporate overview during the needham healthcare conference. the presentation will take place on thursday, april 14, 2022 at 8:45 a.m. edt.
Latest News
2023-06-30 10:43:10 - Zacks Investment Research
Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli Lilly
Eli Lilly (LLY) is set to acquire Sigilon (SGTX) for $14.92 per share, in cash, along with a contingent value right of $111.64 per share.
2023-06-29 13:50:01 - Invezz
Eli Lilly to buy Sigilon Therapeutics on a massive premium
Shares of Sigilon Therapeutics Inc (NASDAQ: SGTX) soared more than 500% today after Eli Lilly & Co (NYSE: LLY) said it will buy the biopharmaceutical company in a deal worth up to $309.6 million. Details of the Lilly-Sigilon agreement Lilly has agreed to pay a total of up to $126.
2023-06-29 12:55:13 - Investopedia
Eli Lilly to Acquire Sigilon Therapeutics
Eli Lilly said it will acquire Sigilon Therapeutics in an all-cash deal worth up to $309.6 million.
2023-06-29 08:13:40 - Reuters
Eli Lilly to buy Sigilon Therapeutics to expand diabetes treatments
Eli Lilly and Co said on Thursday it will acquire all the shares of Sigilon Therapeutics that it did not own to gain access to experimental cell therapies that can provide longer-term solutions for diabetes patients.
2023-06-29 07:59:44 - InvestorPlace
Why Is Sigilon Therapeutics (SGTX) Stock Up 691% Today?
Sigilon Therapeutics (NASDAQ: SGTX ) stock is rocketing on Thursday morning after Eli Lilly (NYSE: LLY ) agrees to acquire the company. The acquisition will see Eli Lilly pay $14.92 per share in cash and one tradeable contingent value right for each share of SGTX stock.
2023-04-18 07:00:00 - GlobeNewsWire
Sigilon Therapeutics to Present at the Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for acute and chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Needham Virtual Healthcare Conference. The presentation will take place on Thursday, April 20, 2023 at 10:15 a.m. EDT.
2023-04-03 22:49:50 - 24/7 Wall Street
10 Best-Performing Penny Stocks in the Health Care Sector
2022-08-04 19:33:26 - Zacks Investment Research
Sigilon Therapeutics, Inc. (SGTX) Reports Q2 Loss, Tops Revenue Estimates
Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of 4.35% and 22.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-05-12 18:48:21 - Zacks Investment Research
Sigilon Therapeutics, Inc. (SGTX) Reports Q1 Loss, Tops Revenue Estimates
Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of -43.33% and 27.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-04-07 07:00:00 - GlobeNewsWire
Sigilon Therapeutics to Present at the Needham Healthcare Conference
CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Needham Healthcare Conference. The presentation will take place on Thursday, April 14, 2022 at 8:45 a.m. EDT.